Volume 127, Issue 7 pp. 1644-1651
Laryngology

Serial in-office laser treatment of vocal fold leukoplakia: Disease control and voice outcomes

Shira L. Koss MD

Corresponding Author

Shira L. Koss MD

Department of Otolaryngology–Head and Neck Surgery, New York Eye and Ear Infirmary of Mount Sinai

Send correspondence to Shira L. Koss, MD, Department of Otolaryngology–Head and Neck Surgery, New York Eye and Ear Infirmary of Mount Sinai, 310 E 14th St, 6th Floor, New York, NY 10003. E-mail: [email protected]Search for more papers by this author
Peter Baxter MD

Peter Baxter MD

Department of Otolaryngology–Head and Neck Surgery, Mount Sinai Medical Center

Search for more papers by this author
Haig Panossian MD

Haig Panossian MD

Department of Otolaryngology–Head and Neck Surgery, Mount Sinai Medical Center

Search for more papers by this author
Peak Woo MD

Peak Woo MD

Department of Otolaryngology–Head and Neck Surgery, Mount Sinai Medical Center

Search for more papers by this author
Michael J. Pitman MD

Michael J. Pitman MD

Department of Otolaryngology–Head and Neck Surgery, Voice and Swallowing Institute, Columbia University Medical Center, New York, New York, U.S.A.

Search for more papers by this author
First published: 13 January 2017
Citations: 32

Presented as a podium presentation at ALA, Chicago, Illinois, U.S.A., May 18–19, 2016.

Financial Disclosure: The authors have no funding, financial relationships, or conflicts of interest to disclose.

Abstract

Objective

Although vocal fold (VF) leukoplakia is commonly treated with in-office laser, there is no data on its long-term effectiveness. This study hypothesizes that VF leukoplakia treated by serial in-office laser results in long-term disease control with maintenance of voice and minimal morbidity.

Study Design

Retrospective review (2008–2015).

Methods

Forty-six patients with VF leukoplakia treated by in-office KTP (potassium titanyl phosphate) or PDL (pulsed dye laser) were included. Median follow-up from final laser treatment was 19.6 months. Main outcomes included: 1) rate of disease control, 2) percentage of disease regression using ImageJ analysis. Secondary outcomes included vocal assessment using the Voice Handicap Index-10 (VHI-10).

Results

Patients underwent a median of 2 (range: 1–6) in-office laser treatments. Time between treatments was median 7.6 months. After final treatment, 19 patients (41.3%) had no disease; two patients (4.3%) progressed to invasive cancer; overall disease regression was median 77.1% (P < 0.001); and VHI-10 score decreased by median 5 (P = 0.037). Thirty-one patients (67.4%) were responders (controlled with in-office treatment only); failures were 13 patients (28.3%) who required operative intervention and two patients (4%) who underwent radiation. Compared to responders, failures demonstrated significantly shorter duration between treatments (median 2.3 vs. 8.9 months, P = 0.038) and significantly less regression (median 49.3% vs. 100%, P = 0.006).

Conclusion

Serial outpatient KTP or PDL treatment of VF leukoplakia is effective for disease control with minimal morbidity and preservation of voice quality. We suggest that patients requiring repeated in-office treatment every 6 months may benefit from earlier operative intervention; other factors associated with in-office success remain unclear.

Level of Evidence

4. Laryngoscope, 127:1644–1651, 2017

The full text of this article hosted at iucr.org is unavailable due to technical difficulties.